SCHEMBL7181409

SCHEMBL7181409

CC(CC(C(=O)c1c(Cl)cccc1Cl)c1ccccc1)P=O

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KCNQ2 O43526 1/20 0.44
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
GPR139 Q6DWJ6 2/20 0.36
MEN1 O00255 1/20 0.36
POLB P06746 1/20 0.36
KMT2A Q03164 1/20 0.36
FEN1 P39748 1/20 0.36
CYP2C19 P33261 1/20 0.36
LMNA P02545 1/20 0.35
HSD17B10 Q99714 1/20 0.35
CRHBP P24387 1/20 0.35
CRHR2 Q13324 1/20 0.35
CXCL8 P10145 1/20 0.35
ALDH1A1 P00352 1/20 0.35
PBRM1 Q86U86 1/20 0.35
CASR P41180 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7175839 0.92 KCNQ2 (0.40) KCNQ2NPC1RAB9AGPR139CXCL8
SCHEMBL7182255 0.89 FABP4 (0.41) KCNQ2MEN1POLBKMT2ALMNA
SCHEMBL7189505 0.84 L3MBTL1 (0.40) KCNQ2MEN1KMT2ACYP2C19LMNA
SCHEMBL7187933 0.81 CA12 (0.44) MEN1POLBKMT2ALMNACRHBP
SCHEMBL7189510 0.80 AKR1C3 (0.38) MEN1POLBKMT2AALDH1A1
SCHEMBL7182204 0.80 KCNQ2 (0.44) KCNQ2NPC1RAB9AMEN1KMT2A
SCHEMBL7181408 0.80 NPSR1 (0.36) KCNQ2MEN1KMT2ALMNAHSD17B10
SCHEMBL7188465 0.77 LMNA (0.36) KCNQ2LMNAHSD17B10CRHBPCRHR2
SCHEMBL7189380 0.77 KCNQ2 (0.43) KCNQ2NPC1RAB9AMEN1KMT2A
SCHEMBL7186973 0.76 CYP1A2 (0.35) MEN1POLBKMT2ACYP2C19LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 KCNQ2 1690/4885NPC1 772/4885RAB9A 1818/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 KCNQ2 1693/4885NPC1 872/4885RAB9A 2155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.